Showing results (11-20 of 651) with videos related to
Sort By:
Pageof 66
BMC Medical Research Methodology|September 2, 2018
Heckman imputation models for binary or continuous MNAR outcomes and MAR predictorsJacques-Emmanuel Galimard, Sylvie Chevret, Emmanuel Curis, et al.Biometrical Journal. Biometrische Zeitschrift|July 7, 2020
Clustering with missing and left-censored data: A simulation study comparing multiple-imputation-based proceduresLilith Faucheux, Matthieu Resche-Rigon, Emmanuel Curis, et al.Journal of Cardiac Failure|February 7, 2013
Continuous positive airway pressure (CPAP) may not reduce short-term mortality in cardiogenic pulmonary edema: a propensity-based analysisRomain Pirracchio, Matthieu Resche Rigon, Alexandre Mebazaa, et al.Journal of Biopharmaceutical Statistics|November 21, 2007
Recent developments in adaptive designs for Phase I/II dose-finding studiesSarah Zohar, Sylvie ChevretJournal of Biopharmaceutical Statistics|March 15, 2003
Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian designSarah Zohar, Sylvie ChevretCritical Care Medicine|March 20, 2019
Center Effects in Hospital Mortality of Critically Ill Patients With Hematologic MalignanciesLucie Biard, Michaël Darmon, Virginie Lemiale, et al.The Lancet. Respiratory Medicine|December 4, 2014
Mortality prediction in intensive care units with the Super ICU Learner Algorithm (SICULA): a population-based studyRomain Pirracchio, Maya L Petersen, Marco Carone, et al.Plos One|August 27, 2013
The effectiveness of inodilators in reducing short term mortality among patient with severe cardiogenic shock: a propensity-based analysisRomain Pirracchio, Jiri Parenica, Matthieu Resche Rigon, et al.Statistical Methods in Medical Research|September 21, 2016
Multiple imputation by chained equations for systematically and sporadically missing multilevel dataMatthieu Resche-Rigon, Ian R WhiteComputer Methods and Programs in Biomedicine|August 28, 2003
Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rulesSarah Zohar, Aurelien Latouche, Mathieu Taconnet, et al.Pageof 66